Recommended Citation
Lokhandwala T, Aly A, Farrelly E, Willey JP, Lamerato LE, Healey M, Coutinho AD, and Seal BS. Management of hepatocellular carcinoma from diagnosis in routine clinical practice. Hepat Oncol 2023; 9(4):Hep45.
Document Type
Article
Publication Date
12-1-2022
Publication Title
Hepat Oncol
Abstract
AIM: To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network.
MATERIALS & METHODS: A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient.
RESULTS: Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72-82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy.
CONCLUSION: This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.
PubMed ID
37009420
Volume
9
Issue
4
First Page
45
Last Page
45
